Author:
Wilson Brooke E.,Desnoyers Alexandra,Al-Showbaki Laith,Nadler Michelle B.,Amir Eitan
Abstract
AbstractDisease-free survival (DFS) comprises both breast cancer and non-breast cancer events. DFS has not been validated as a surrogate endpoint for overall survival (OS) in most breast cancer subtypes. We assessed changes to the type of events contributing to DFS over time. We identified adjuvant studies in breast cancer (BC) from 2000 to 2020 where the endpoint was DFS. We examined change in distant DFS events and the BC-related DFS using univariable and multivariable linear regression. Data were reported quantitatively using the Burnand criteria irrespective of statistical significance. We included 84 studies (88 cohorts), comprising 212,191 participants, 41,604 DFS events and 23,205 distant DFS events. The DFS event rate/100 participants/year has declined modestly over time (ß − 0.34, p = 0.001). Start year was negatively associated with distant DFS events (ß − 0.58, p < 0.0001); however, the effect was lost after adjusting for follow-up time (ß − 0.18, p = 0.096). The average number of BC-related events/100 participants/year also declined over time (ß − 0.28, p = 0.009). In multivariable analysis, start year and ER expression were quantitatively associated with distant DFS events and BC-related DFS events. DFS events have declined over time driven by a reduction in BC related events. As DFS events are increasingly defined by non-BC events, there will be limited surrogacy between DFS and OS.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Kay, A. et al. Randomized controlled trials in the era of molecular oncology: Methodology, biomarkers, and end points. Ann. Oncol. 23(6), 1646–1651 (2012).
2. Administration, F.A.D. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. https://www.fda.gov/media/71195/download (2018). (Accessed 12 January 2021).
3. Chen, E. Y. et al. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern. Med. 179(5), 642–647 (2019).
4. Gyawali, B., Hey, S. P. & Kesselheim, A. S. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 21, 100332 (2020).
5. Saad, E. D. et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: A systematic review and meta-analysis. Lancet Oncol. 20(3), 361–370 (2019).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献